Company: CORT
Filing Date: 2025-03-31
Form Type: 8-K
Source: 0001193125-25-067871
Chunk: 0

Company: CORCEPT THERAPEUTICS INC
Filing Date: 2025-03-31
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01. Other Events.

On March 31, 2025, Corcept Therapeutics Incorporated (the “ Company”) issued a press release announcing that ROSELLA, the Company’s pivotal Phase 3 trial of relacorilant plus nab-paclitaxelin patients with platinum-resistant ovarian cancer, met its primary endpoint of improved progression-free survival, as assessed by blinded independent central review(PFS-BICR). The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.